MedTrace Logo

CISPLATIN + AZD-1775 In Breast Cancer

NCT03012477 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-11-23

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions involved in this study are:

* Cisplatin
* AZD1775

Conditions

  • Triple-negative Metastatic Breast Cancer

Interventions

DRUG

Cisplatin

chemotherapy

DRUG

AZD1775

Wee1 tyrosine kinase inhibitor

Sponsors & Collaborators

Principal Investigators

  • Sara Tolaney, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-18
Primary Completion
2019-05-07
Completion
2020-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03012477 on ClinicalTrials.gov